Supernus Pharmaceuticals Completes Merger with Indivior, Shifting to a Diversified CNS Biopharmaceutical Focus

On November 2 2026, Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) and Indivior Pharmaceuticals, Inc. announced the completion of a merger that will combine their operations into a single entity focused on central nervous system (CNS) diseases and disorders. The transaction will be reflected in a new ticker symbol—INDV—for the combined company on the Nasdaq Global Market, with the former Supernus ticker expected to resume trading as SUPN the following day.

Transaction Structure and Shareholder Impact

  • All‑stock combination: Former Supernus shareholders will receive 1.5401 shares of the newly combined company for each share of Supernus stock they hold.
  • Ownership distribution: Post‑merger, Indivior shareholders will own approximately 56.5 % of the fully diluted capital, while former Supernus shareholders will hold about 43.5 %.
  • Special cash dividend: Indivior shareholders who hold stock immediately before the closing will be entitled to a $1.0 billion special cash dividend.

The dividend will be financed through a combination of a $650 million Citibank term loan and the combined entity’s existing cash reserves.

Leadership and Governance

  • Chief Executive Officer: Jack Khattar, formerly of Indivior, will assume the CEO role for the combined company.
  • Board Chair: Tony Kingsley, also from Indivior, will serve as the new board chair.

Strategic Rationale

The merger positions the new company as a diversified CNS biopharmaceutical leader with an 11‑product portfolio spanning epilepsy, conduct disorder, Parkinson’s disease, ADHD, depression, and other neurological and psychological conditions. The combined cash‑flow profile and capital resources are expected to accelerate product development, support the existing pipeline, and enable the pursuit of strategic growth opportunities.

Market Context

Prior to the merger announcement, Supernus traded at $41.92 on October 29, 2026, with a market capitalization of approximately $2.44 billion. The company’s price‑to‑earnings ratio was reported at –22.22, reflecting its ongoing investment in clinical‑stage therapeutics. The merger is anticipated to create a more robust platform for commercialization and R&D, potentially enhancing shareholder value over the long term.

Conclusion

The integration of Supernus and Indivior marks a significant milestone in the CNS therapeutic arena. By combining complementary product lines, expanding financial capacity, and unifying leadership, the new entity aims to strengthen its position as a leading biopharmaceutical company dedicated to addressing complex neurological and psychological disorders.